Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Cervarix™. Human papillomavirus vaccine
Raphael P. Viscidi
, Keerti V. Shah
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cervarix™. Human papillomavirus vaccine'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Human Papillomavirus Vaccine
100%
Cervarix
100%
HPV16
66%
Phase II Study
50%
Interim Analysis
33%
Immunogenic
16%
Young Women
16%
Alum
16%
Genital Tract
16%
Antibody Titer
16%
Cervical Cancer
16%
Cervix
16%
Vaccine Response
16%
Virus-like
16%
Human Papillomavirus Types
16%
Cross-protection
16%
Seroconversion Rate
16%
Cervical Intraepithelial Neoplasia Grade 2
16%
Adjuvanted
16%
Natural Infection
16%
Phosphoinositide Lipid
16%
Medicine and Dentistry
Wart Virus Vaccine
100%
Infection
57%
Human Papillomavirus Type 16
42%
Interim Analysis
28%
Cervix
14%
Seroconversion
14%
Cervical Intraepithelial Neoplasia
14%
Cervical Cancer
14%
Cross Protection
14%
Phosphoryl Lipid A
14%
Human Papillomavirus Type 18
14%
Human Papillomavirus Type 31
14%
Human Papillomavirus Type 45
14%
Virus Like Particle Vaccine
14%
Pharmacology, Toxicology and Pharmaceutical Science
Wart Virus Vaccine
100%
Infection
57%
Human Papillomavirus Type 16
42%
Uterine Cervix Cancer
14%
Human Papillomavirus Type 18
14%
Phosphoryl Lipid A
14%
Uterine Cervix Carcinoma in Situ
14%
Virus Like Particle Vaccine
14%
Human Papillomavirus Type 31
14%
Human Papillomavirus Type 45
14%
Immunology and Microbiology
Cervarix
100%
Human Papillomavirus Type 16
42%
Vaccine Efficacy
28%
Antibody Titer
14%
Seroconversion
14%
Human Papillomavirus Type 18
14%
Cross Protection
14%
Phosphoryl Lipid A
14%
Human Papillomavirus Type 31
14%
Human Papillomavirus Type 45
14%
Virus Like Particle Vaccine
14%